Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antidepressant Drugs: MAOIs and Other Agents01:23

Antidepressant Drugs: MAOIs and Other Agents

429
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
429
Desensitization and Tachyphylaxis01:20

Desensitization and Tachyphylaxis

2.5K
Tachyphylaxis is described as a rapid decrease in response to a drug after repeated or continuous administration of the same drug dose. It is a phenomenon where the body becomes less responsive to a particular substance or intervention over time, requiring higher doses or stronger interventions to achieve the same effect. It results from adaptive changes in the body's receptors, signaling pathways, or physiological processes that occur in response to prolonged exposure to a stimulus.
2.5K
Bipolar Disorder01:30

Bipolar Disorder

168
Bipolar disorder is a chronic mental health condition marked by significant mood fluctuations, including episodes of mania and depression. Elevated energy levels, heightened mood or irritability, impulsive behavior, reduced sleep needs, rapid speech, racing thoughts, inflated self-esteem, and distractibility characterize mania. Individuals with bipolar disorder often alternate between depressive and manic states, with periods of emotional stability lasting an average of six months to a year.
168
Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance01:23

Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance

340
The elimination half-life and drug clearance of drugs following nonlinear kinetics can vary with dosage. The Michaelis-Menten parameters and drug concentration influence these factors. As the dose increases, the elimination half-life tends to lengthen, resulting in a reduction in clearance and a disproportionately larger area under the curve. The total clearance can be derived from the Michaelis-Menten equation for drugs following a one-compartment model.
A study on guinea pigs examined the...
340
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

238
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
238
Psychosis: Goals of Pharmacotherapy01:26

Psychosis: Goals of Pharmacotherapy

256
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation.
256

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Lichen Planus Pigmentosus Localized to the Glans Penis: A Rare Presentation Treated With Ruxolitinib.

Cureus·2026
Same author

Subacute cutaneous lupus erythematosus secondary to intravenous immunoglobulin therapy for chronic inflammatory demyelinating polyneuropathy: A case report.

JAAD case reports·2026
Same author

Pregnancy associated anti-TIF1 dermatomyositis responsive to intravenous immunoglobulin.

JAAD case reports·2024
Same author

Painful Nodules With a Crawling Sensation.

Cutis·2023
Same author

Artificial intelligence-derived dermatology case reports are indistinguishable from those written by humans: A single-blinded observer study.

Journal of the American Academy of Dermatology·2023
Same author

Superficial solitary fibrous tumor masquerading as a dermoid cyst: a case report.

AME case reports·2022

Related Experiment Video

Updated: Oct 14, 2025

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
11:39

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis

Published on: July 11, 2013

39.1K

Erythrodermic Psoriasis Exacerbated by Bupropion.

Michael G Foss1, Timothy Nyckowski1, William Steffes1

  • 1Dermatology, Kansas City University-Graduate Medical Education Consortium/Advanced Dermatology and Cosmetic Surgery Orlando Dermatology Residency Program, Orlando, USA.

Cureus
|November 8, 2021
PubMed
Summary

Erythroderma, a severe psoriasis form, can be triggered by bupropion, an antidepressant. Physicians should recognize this under-recognized, potentially life-threatening side effect, especially in patients with common psoriatic comorbidities.

Keywords:
bupropiondrug rashdrug reactionerythrodermaerythrodermic psoriasispsoriasis

More Related Videos

Author Spotlight: Self-Assessment Protocol for Predicting Psoriatic Arthritis in Psoriasis Patients
02:28

Author Spotlight: Self-Assessment Protocol for Predicting Psoriatic Arthritis in Psoriasis Patients

Published on: March 1, 2024

533
Studying Chronic Exposure of Mice to Ultraviolet B Radiation
03:20

Studying Chronic Exposure of Mice to Ultraviolet B Radiation

Published on: August 19, 2025

1.2K

Related Experiment Videos

Last Updated: Oct 14, 2025

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
11:39

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis

Published on: July 11, 2013

39.1K
Author Spotlight: Self-Assessment Protocol for Predicting Psoriatic Arthritis in Psoriasis Patients
02:28

Author Spotlight: Self-Assessment Protocol for Predicting Psoriatic Arthritis in Psoriasis Patients

Published on: March 1, 2024

533
Studying Chronic Exposure of Mice to Ultraviolet B Radiation
03:20

Studying Chronic Exposure of Mice to Ultraviolet B Radiation

Published on: August 19, 2025

1.2K

Area of Science:

  • Dermatology
  • Pharmacology

Background:

  • Erythroderma is a severe, potentially fatal manifestation of psoriasis.
  • Medication reactions are known triggers for erythroderma.
  • Bupropion is prescribed for depression, smoking cessation, and weight loss.

Observation:

  • A 62-year-old female developed erythrodermic psoriasis after being prescribed bupropion for depression.
  • Bupropion is an under-recognized cause of psoriasis exacerbation, particularly in the United States.

Findings:

  • Bupropion can trigger erythroderma, a severe form of psoriasis.
  • This adverse drug reaction is under-recognized in clinical practice.

Implications:

  • Healthcare providers must be aware of bupropion's potential to induce erythroderma.
  • Awareness is crucial for managing psoriatic patients with comorbidities like depression, obesity, and tobacco use.
  • Prompt recognition and management can prevent severe outcomes associated with erythrodermic psoriasis.